論文・総説 - 小宮　力

1. Fukuda T., Bouchi R., Asakawa M., Takeuchi T., Shiba K., Tsujimoto K., Komiya C., Yoshimoto T., Ogawa Y., Yamada T.. Sarcopenic obesity is associated with a faster decline in renal function in people with type 2 diabetes DIABETIC MEDICINE. 2019.10; ( DOI )

2. Miyachi Yasutaka, Tsuchiya Kyoichiro, Shiba Kumiko, Mori Kentaro, Komiya Chikara, Ogasawara Naomi, Ogawa Yoshihiro. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition SCIENTIFIC REPORTS. 2018.10; 8 (1): 16113. ( PubMed, DOI )

3. Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh, Takayoshi Suganami, Yoshihiro Ogawa. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Scientific Reports. 2018.02; 8 (1): 2362. ( PubMed, DOI )

4. Chikara Komiya, Miyako Tanaka, Kyoichiro Tsuchiya, Noriko Shimazu, Kentaro Mori, Shunsaku Furuke, Yasutaka Miyachi, Kumiko Shiba, Shinobu Yamaguchi, Kenji Ikeda, Kozue Ochi, Kazuhiko Nakabayashi, Ken-Ichiro Hata, Michiko Itoh, Takayoshi Suganami, Yoshihiro Ogawa. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Scientific Reports. 2017.03; 7 44754. ( PubMed, DOI )

5. Yasutaka Miyachi, Kyoichiro Tsuchiya, Chikara Komiya, Kumiko Shiba, Noriko Shimazu, Shinobu Yamaguchi, Michiyo Deushi, Mizuko Osaka, Kouji Inoue, Yuta Sato, Sayaka Matsumoto, Junichi Kikuta, Kenjiro Wake, Masayuki Yoshida, Masaru Ishii, Yoshihiro Ogawa. Roles for Cell-Cell Adhesion and Contact in Obesity-Induced Hepatic Myeloid Cell Accumulation and Glucose Intolerance. Cell Reports. 2017.03; 18 (11): 2766-2779. ( PubMed, DOI )

6. Chikara Komiya, Kyoichiro Tsuchiya, Kumiko Shiba, Yasutaka Miyachi, Shunsaku Furuke, Noriko Shimazu, Shinobu Yamaguchi, Kazuo Kanno, Yoshihiro Ogawa. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE. 2016.03; 11 (3): e0151511. ( PubMed, DOI )

7. Miyako Tanaka, Kenji Ikeda, Takayoshi Suganami, Chikara Komiya, Kozue Ochi, Ibuki Shirakawa, Miho Hamaguchi, Satoshi Nishimura, Ichiro Manabe, Takahisa Matsuda, Kumi Kimura, Hiroshi Inoue, Yutaka Inagaki, Seiichiro Aoe, Sho Yamasaki, Yoshihiro Ogawa. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nature Communications. 2014.09; 5 4982. ( PubMed, DOI )

8. 小宮 力, 山田哲也. 糖尿病の診断（病歴聴取と身体所見の取り方，診断のための検査） 日本医師会雑誌. 2021.10; 150 (2): S157-S160.

9. 小宮 力, 吉本 貴宣. 【NASH/NAFLDの新知見】 治療　SGLT2阻害剤 肝・胆・膵. 2018.04; 76 (4): 758-769. ( 医中誌 )

10. 小宮 力，菅波 孝祥，小川 佳宏. 【最新臨床高血圧学-高血圧治療の最前線-】 高血圧発症・進展因子の関わり　慢性炎症 日本臨床. 2014.08; 72 (増刊6): 248-252. ( 医中誌 )

11. 小宮 力，菅波 孝祥，小川 佳宏. 【慢性炎症と本態-線維化・免疫・炎症の各視点から-】 慢性炎症と生活習慣病 BIO Clinica. 2013.11; 28 (12): 1134-1138. ( 医中誌 )

12. 佐藤 文紀，辻野 元祥，宮地 康高，石本 育栄，永田 友香，小宮 力，大橋 琢也，黒澤 由貴子，櫻田 麻耶，西田 賢司，小川 佳宏. 2型糖尿病患者における持続血糖モニターを用いたリラグルチド導入例の検討 糖尿病. 2013.07; 56 (7): 430-435. ( 医中誌 )

13. 小宮 力，菅波 孝祥，小川 佳宏. 【高血圧診療のすべて】　新しい病態理解と治療への展望 慢性炎症(解説/特集) 日本医師会雑誌. 2013.06; 142 (特別1): S72-S75. ( 医中誌 )

14. 小宮 力，菅波 孝祥，小川 佳宏. 【臨床医にもわかる糖尿病基礎研究】 メタボリックシンドロームと慢性炎症 ホルモンと臨床. 2012.11; 60 (11): 919-926. ( 医中誌 )